Monday, July 4, 2022
  • Advertise
  • Submit Story Idea
  • Submit Event
  • Calendar
Arlington Today Magazine
  • Home
  • Categories
    • Arlington News
    • People
    • Community
    • Commentary
    • Business and Education
    • Featured
    • Wellness
    • Scene
    • Design and Interiors
    • Uncategorized
  • Digital Editions
  • Join the Newsletter
  • Subscribe
  • Contact Us
No Result
View All Result
  • Home
  • Categories
    • Arlington News
    • People
    • Community
    • Commentary
    • Business and Education
    • Featured
    • Wellness
    • Scene
    • Design and Interiors
    • Uncategorized
  • Digital Editions
  • Join the Newsletter
  • Subscribe
  • Contact Us
No Result
View All Result
Arlington Today Magazine

Killing bugs: UTA team earns a grant to try to thwart burgeoning drug-resistant bacterial infections

By Linsey Retcofsky

ArlingtonToday Magazine by ArlingtonToday Magazine
January 3, 2022
in Business and Education
0 0
0
Killing bugs: UTA team earns a grant to try to thwart burgeoning drug-resistant bacterial infections
0
SHARES
116
VIEWS
Share on FacebookShare on Twitter
Texas Health Resource Breast Care Oct 2020

Experts predict that without intervention, the problem of multi-drug-resistant bacterial infections could be catastrophic by 2050, killing nearly 10 million people each year.

  To seek solutions, the National Institutes of Health awarded a five-year, $1.8 million grant to Joseph Boll, assistant professor of biology at The University of Texas at Arlington, to identify and inhibit the defense mechanisms of Acinetobacter baumannii, a pathogen that thrives in hospitals and clinical settings.

Related posts

July 1, 2022

July 1, 2022

  A. baumannii can cause infections in the blood, urinary tract and lungs, or in wounds in other parts of the body. Infections are generally treated with antibiotics, but many strains are resistant to medication, including carbapenems, a class of highly effective antibiotics usually reserved for severe multi-drug-resistant bacterial infections.

  “In previous research, we discovered that when A. baumannii experiences stress, such as antibiotic treatment, it modifies its cell envelope to tolerate the antibiotic for extended periods of time,” Boll says. “Specific modifications allow the bacteria to survive long enough to acquire true antibiotic resistance, which can lead to antibiotic treatment failure. This can happen within 24 hours of antibiotic exposure.”

  Boll’s team expects to identify what adaptations in the cell envelope allow the pathogen to survive in the presence of antibiotics and how survival contributes to the acquisition of true resistance.

  In a recent study titled “Septal Class A Penicillin-Binding Protein Activity and ld-Transpeptidases Mediate Selection of Colistin-Resistant Lipooligosaccharaide-Deficient Acinetobacter baumannii,” which was published in the journal mBio, the team showed that two LD-transpeptidase enzymes remodel A. baumannii’s cell envelope to promote its survival when under stress, such as the kind experienced during antibiotic treatment.

  Armed with this breakthrough, Hannah Bovermann, a senior double-major in biology and microbiology, is dissecting the genes that encode the bacteria’s LD-transpeptidases to learn what stress conditions induce their activation. She isolates the LD-transpeptidase promoters, the part of the DNA that controls when other parts of DNA are used, and glues it to a different gene whose function is to turn the bacterial cell blue. When the cell is in an environment where it wants to modify its cell envelope to protect itself, it turns blue, and Bovermann can observe the timing of the change.

  To provoke this reaction, she administers antibiotics, experiments with various temperature changes, exposes the cell to pH gradients and subjects the cell to nutrient deprivations.

  “Each response brings us closer to an understanding of how cell envelope modifications keep the bacterial cell intact in stress,” Bovermann says.

  The researchers hope to find new targets on the cell surface for antibiotics to attack, strengthening existing medications’ potency against A. baumannii infections.

  Drug-resistant bacteria have cornered health care providers into using combinatorial therapies, where multiple drugs are employed to treat bacterial infections, but even those methods are becoming increasingly ineffective, Boll says.

  “It has become a game. Researchers discover a new antimicrobial, then bacteria become resistant to it. We are running out of options,” Boll says. “Bacterial resistance is quickly outpacing new antibiotic development.”

Related Posts

  • UTA Groundbreaking

    Check out these scene snapshot's from UTA's Groundbreaking.

  • UTA Vaccinations

    Check out these Scene Snapshots from the new UTA Covid-19 vaccination site.

  • How 'Bout Those UTA Mavs?

    The UTA basketball team is off to a great start...

Tags: UTA Today
Arlington Today Magazine

Arlington Texas Area News and Events Magazine

Follow us on social media:

Recent News

  • (no title)
  • (no title)
  • (no title)

Category

  • Arlington News
  • Business and Education
  • Commentary
  • Community
  • Design and Interiors
  • Featured
  • People
  • Scene
  • Sports
  • Uncategorized
  • Wellness

Recent News

July 2, 2022

July 2, 2022
  • Advertise
  • Submit Story Idea
  • Submit Event
  • Calendar

© 2020 Arlington Today - Designed by Advent Trinity - Powered by Metrotechs

No Result
View All Result
  • Home
  • Categories
    • Arlington News
    • Community
    • People
    • Commentary
    • Business and Education
    • Featured
    • Wellness
    • Scene
    • Design and Interiors
  • Digital Editions
  • Join the Newsletter
  • Contact Us

© 2020 Arlington Today - Designed by Advent Trinity - Powered by Metrotechs

Login to your account below

Forgotten Password? Sign Up

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add Arlington Today Magazine to your Homescreen!

Add